Mark Frigerio

Vice President, Head of Platform Technology & Science at Bicycle Therapeutics

Speaker

Mark received his PhD from UCL in 2003, then post graduate research in the laboratory of Professor Karl Hale at UCL focused on synthesising the antitumour macrolide Bryostatins resulting in the enantioselective formal total synthesis of Bryostatin 7. Mark then worked in various roles at KuDOS Pharmaceuticals, Pharminox and PolyTherics/Abzena leading various Medicinal Chemistry and cross-functional multidisciplinary teams. He is an expert in the design and development of Antibody Drug Conjugate (ADC) linkers and was instrumental in building Abzena’s site-specific ThioBridge® conjugation technology platform, now in clinical trials, for the production of stable and homogeneous ADCs, as well as Abzena’s site-specific polymer PEGylation linker technology including TheraPEG™, CyPEG™ and HiPEG™, for the half-life extension of peptides and proteins. Mark joined Bicycle Therapeutics in 2022 heading the Peptide, Organic and Medicinal Chemistry Groups in the UK, involving the design and development of bicyclic peptide drugs and conjugates. Mark’s current role as Head of Platform Technology & Science is leading the preclinical discovery and platform research teams that drive the early portfolio. Mark also received his eMBA in 2021 from the Judge Business School, University of Cambridge centred on researching high performance team development. Mark has 42 publications and patents in the field of early stage drug discovery.